Products
CE Global Private Equity offers a wide range of investment products and services for retail and corporate investors.
Investment Performance Case Study
RayzeBio Inc.
Welcome to the Investment Performance Case Study of RayzeBio Inc. , which follows our clients' journeys of investing in RayzeBio Inc. between 15th Sep, 2023 and 26th Dec, 2023, during which the recorded share price produced a gain of 247%.
NASDAQ:RYZB
Introduction
RayzeBio is a clinical-stage biotechnology company specializing in radiopharmaceutical therapies for cancer treatment. Their lead program, RYZ101, is in a Phase 3 clinical trial targeting tumors that express somatostatin receptor type 2 (SSTR2). The therapy delivers a potent alpha particle radioisotope, Actinium-225, directly to cancer cells
The RayzeBio Inc. Investment Case
RayzeBio was a clinical-stage biotechnology company developing radiopharmaceutical therapies for cancer. Its approach centred on targeted radioactive medicines designed to deliver radiation directly to tumour cells while limiting exposure to surrounding healthy tissue.
The Transaction
RayzeBio completed its initial public offering in September 2023 at $18.00 per share, with trading beginning on 15 September. The listing provided the company with additional capital to advance its radiopharmaceutical development pipeline.
Strategic Acquisition
On 26 December 2023, Bristol Myers Squibb announced an agreement to acquire RayzeBio for $62.50 per share in cash. The acquisition price represents an increase of approximately 247.2% over the $18.00 IPO price in little more than three months, making the transaction a particularly notable example of value creation culminating in a strategic corporate acquisition.
- Entry Event: Initial Public Offering
- Outcome Event: Strategic Acquisition
- Study Period: 15 September 2023 – 26 December 2023
- Entry Price: $18.00
- Acquisition Price: $62.50 per share
- Acquirer: Bristol Myers Squibb
Case Overview
| Company Name : | RayzeBio Inc. |
|---|---|
| Sector : | Radiopharmaceutical therapies |
| Event Type : | IPO → Acquisition |
| Buy Advice : | 2023-09-15 |
| Sell Advice : | 2023-12-26 |
| Buy Price : | 18.00 (USD) |
| Sell Price : | 62.50 (USD) |
| Profit(%) : | 247% |
Case Studies
Related Studies
Jin Medical International Ltd.
The case study of the Jin Medical International Ltd. IPO in 2024
Oxford Nanopore Technologies
The case study of the Oxford Nanopore Technologies IPO in 2021
